-
Outstanding Scientific Achievement Award lecturer shares an unexpected journey into the field of diabetes by way of brown fat
Shingo Kajimura, PhD, explained how his curiosity about surviving cold Michigan winters led to the discovery that brown fat is a potent metabolic regulator that can control insulin and glucose levels independent of thermogenesis and independent of the canonical uncoupling protein 1 pathway.
-
Kelly West Award recipient combines data-driven knowledge with care
In her award lecture, epidemiologist Juliana C.N. Chan, MBChB, MD, FHKAM, FHKCP, FRCP, detailed her decades of data-driven research and her personal experience working with patients in a major metropolis transformed by global modernization.
-
ADA President, Medicine & Science: Closing the circle from progress to promise is our unfinished journey
While the diabetes community has yet to reach the ultimate goal of improving health outcomes for every person living with diabetes, great strides have been made. Rita Rastogi Kalyani, MD, MHS, the ADA’s President, Medicine & Science, said the path forward needs to include professional education and advocacy.
-
Banting Medalist explains how beta cells hold the key to type 2 diabetes
Steven E. Kahn, MB, ChB, accepted the Banting Medal for Scientific Achievement on Sunday at the Scientific Sessions. His lab identified a hyperbolic relationship between beta cell response and insulin sensitivity in the early 1990s. In his award lecture, he discussed how this dynamic fits into pathogenesis and progression of type 2 diabetes.
-
Standards of Care in Diabetes—2025 brings updates to practice
New and revised recommendations for the care of people living with diabetes cover glucose-lowering pharmacotherapy, diabetes, technology, population health considerations, and more. Naushira Pandya, MD, CMD, gave an overview of the updated Standards of Care for older adults with diabetes.
-
STRIDE is a first step in addressing unmet needs in comorbid PAD and type 2 diabetes
STRIDE principal investigator Subodh Verma, MD, PhD, FRCSC, and others explained how semaglutide can change the trajectory of disease in individuals with type 2 diabetes and peripheral artery disease.
-
REDEFINE trials advance combination treatment for weight management
Experts discussed findings from two phase 3 studies that evaluated the efficacy of combined treatment with an amylin analog and a glucagon-like peptide 1 (GLP-1) receptor agonist in inducing weight loss in individuals living with obesity or overweight.
-
Speakers will dispel myths about muscle and energy expenditure
Lara Dugas, PhD, MPH, and other panelists will examine the impact of common misconceptions and summarize new insights about the dynamics of muscle mass, energy expenditure, and individual metabolism.
Presenter Profiles
